--- title: "Psyence Biomedical (PBM) news: offering" url: "https://aibio.space/companies/psyence-biomedical/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PBM offering news: Psyence Biomedical agrees to $2.0 million private placement with warrants. Psyence Biomedical Ltd. (NASDAQ: PBM), Canada." --- PBM Psyence Biomedical Ltd. NASDAQ · Canada # Psyence Biomedical (PBM) news PBM offering news Listings · 2026-02-19 ## [Psyence Biomedical shareholders approve share consolidation of up to 250:1](https://aibio.space/news/psyence-biomedical-shareholders-approve-share-consolidation-up-250-1/) Shareholders gave Psyence's board authority to consolidate the common shares at a ratio of up to 250:1, but the board has not set a ratio or timing, and the company says a consolidation may never happen. ## Latest Psyence Biomedical news 1. 2024-12-31 Listings [Psyence Biomedical agrees to $2.0 million private placement with warrants](https://aibio.space/news/psyence-biomedical-agrees-2-0-million-private-placement-warrants/) The deal covers 1,000,000 common shares at $2.00 each, plus two series of warrants. H.C. Wainwright & Co. is placement agent. ## Psyence Biomedical at a glance - **Ticker**: PBM - **Listing**: NASDAQ - **Country**: Canada - **Cash, Sep 30, 2025**: $7.1 million ### Related companies - [Arch Biopartners](https://aibio.space/companies/arch-biopartners/) TSXV: ARCH - [Modern Mobility Aids](https://aibio.space/companies/modern-mobility-aids/) OTC: MDRM - [Helus Pharma](https://aibio.space/companies/helus-pharma/) NEO: HELP - [NORTH BUD FARMS INC](https://aibio.space/companies/north-bud-farms/) OTC: NOBDF - [Satellos Bioscience](https://aibio.space/companies/satellos-bioscience/) TSX: MSCL - [Telescope Innovations](https://aibio.space/companies/telescope-innovations/) CSE: TELI - [Appili Therapeutics](https://aibio.space/companies/appili-therapeutics/) TSXV: APLI.H - [InMed Pharmaceuticals](https://aibio.space/companies/inmed-pharmaceuticals/) NASDAQ: INM ### Also on NASDAQ - [Palisade Bio](https://aibio.space/companies/palisade-bio/) PALI - [Rapport Therapeutics](https://aibio.space/companies/rapport-therapeutics/) RAPP - [NovaBridge Biosciences](https://aibio.space/companies/novabridge-biosciences/) NBP - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) SABS - [Xenon Pharmaceuticals](https://aibio.space/companies/xenon-pharmaceuticals/) XENE - [Lantheus Holdings](https://aibio.space/companies/lantheus/) LNTH ## What Psyence Biomedical does Psyence Biomedical Ltd. is a clinical-stage biopharmaceutical company that works with natural psilocybin for palliative care treatment. Its product used in the Phase IIb study is NPX-5, described as capsules containing 25mg of naturally sourced psilocybin. The field of use is anxiety and depression, including associated ailments such as PTSD, stress, grief and adjustment disorder within the context of palliative care. The company's principal capital expenditures in progress consist of funding that Phase IIb trial in Australia, conducted through Southern Star Research Pty Ltd and its subsidiary Psyence Australia. It replaced PEX010, a botanical drug candidate licensed from Filament Health Corp., with NPX-5 from PsyLabs as the candidate in the Phase IIb study. The company has also invested in PsyLabs, which the text describes as a privately held company headquartered in the British Virgin Islands that focuses on psychedelic active pharmaceutical ingredients and extracts, and which it describes as part of a multi-asset, vertically integrated platform for psychedelic-based therapeutics. The company's common shares and public warrants trade on Nasdaq under PBM and PBMWW, following a business combination with Newcourt Acquisition Corp. that concluded on January 25, 2024. | Product or program | What it is | Stage | |---|---|---| | NPX-5 | Capsules containing 25mg naturally sourced psilocybin for anxiety and depression | Phase IIb | Summarised from the company's [20-F filed Jun 22, 2026](https://www.sec.gov/Archives/edgar/data/1985062/000121390026070607/ea0294983-20f_psyence.htm). ## Psyence Biomedical annual financials | Line | FY ended Mar 31, 2025 | FY ended Mar 31, 2024 | |---|---|---| | Research and development | [$342,168](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/) | [$954,593](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/) | | Net income (loss) | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/) | [-$51.2 million](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/) | | Cash from operations | [-$3.7 million](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/) | [-$2.9 million](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/) | | Cash and equivalents | [$6.1 million](https://www.sec.gov/Archives/edgar/data/1985062/000121390025113106/) | [$733,188](https://www.sec.gov/Archives/edgar/data/1985062/000121390025113106/) | Latest balance sheet, Sep 30, 2025 (6-K): cash and equivalents $7.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Psyence Biomedical Has Psyence Biomedical raised money recently? Our latest story on this, dated Dec 31, 2024: "Psyence Biomedical agrees to $2.0 million private placement with warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/psyence-biomedical-agrees-2-0-million-private-placement-warrants/). What is the ticker symbol of Psyence Biomedical? Psyence Biomedical Ltd. trades under the ticker PBM on NASDAQ. Where is Psyence Biomedical listed? Psyence Biomedical Ltd. is listed on NASDAQ. What is the SEC CIK of Psyence Biomedical? The SEC Central Index Key (CIK) for Psyence Biomedical Ltd. is 1985062. Its filings are on SEC EDGAR. How many shares does Psyence Biomedical have outstanding? 2,293,277 shares as of 2026-03-31, per the cover page of its 20-F filed 2026-06-22. Which country or territory is Psyence Biomedical listed under? Our directory records Psyence Biomedical Ltd. under Canada. What does Psyence Biomedical do? Our directory classifies Psyence Biomedical Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Psyence Biomedical? The ISIN recorded for Psyence Biomedical Ltd. is CA74449F4078. Does aibio.space cover Psyence Biomedical? aibio.space lists Psyence Biomedical Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Psyence Biomedical incorporated? SEC records list its state or country of incorporation as A6. What does Psyence Biomedical develop? Psyence Biomedical Ltd. is a clinical-stage biopharmaceutical company that works with natural psilocybin for palliative care treatment. Its product used in the Phase IIb study is NPX-5, described as capsules containing 25mg of naturally sourced psilocybin. What is NPX-5 from Psyence Biomedical? NPX-5: Capsules containing 25mg naturally sourced psilocybin for anxiety and depression Stage: Phase IIb. Is Psyence Biomedical profitable? Psyence Biomedical Ltd. reported net income of $1.0 million for the fiscal year ended Mar 31, 2025, and used $3.7 million of cash in operations, per its annual report to the SEC. How much does Psyence Biomedical spend on research and development? $342,168 in the fiscal year ended Mar 31, 2025, per its annual report. How much cash does Psyence Biomedical have? $7.1 million in cash at Sep 30, 2025, per its 6-K. ## Investor discussion: Psyence Biomedical Members talk about Psyence Biomedical (PBM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Psyence Biomedical, newest first. Each line links the filing it comes from. 1. 2026-08-26 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390026093628/ea0302774-f3_psyence.htm) 2. 2026-02-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390026018155/ea027700001ex99-1_psyence.htm) 3. 2026-02-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390026015229/ea027670901ex99-1_psyence.htm) 4. 2026-01-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390026009093/ea027450401ex99-1_psyence.htm) 5. 2026-01-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390026003680/ea027267801ex99-1_psyence.htm) 6. 2025-11-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390025108225/ea026479201ex99-1_psyence.htm) 7. 2025-08-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390025081729/ea025502801ex99-1_psyence.htm) 8. 2025-06-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390025057779/ea024690601ex99-1_psyence.htm) 9. 2025-06-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390025053433/ea024526901ex99-1_psyence.htm) 10. 2025-05-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390025040150/ea0241127ex99-1_psyence.htm) 11. 2025-04-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390025034643/ea023930301ex99-1_psyence.htm) 12. 2025-04-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390025031060/ea023763501ex99-1_psyence.htm) 13. 2025-04-01 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390025027251/ea023655101ex99-1_psyence.htm) 14. 2025-03-04 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000121390025020258/ea0231303-f3_psyence.htm) 15. 2025-01-24 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1.htm) 16. 2024-12-31 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000110465924132846/tm2431883d2_ex99-1.htm) 17. 2024-12-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000110465924131392/tm2431883d1_ex99-1.htm) 18. 2024-12-20 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1.htm) 19. 2024-12-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000110465924124932/tm2429989d1_ex99-1.htm) 20. 2024-11-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000110465924121840/tm2429142d1_ex99-1.htm) 21. 2024-11-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1985062/000110465924116934/tm2428278d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PBM on TradingView](https://www.tradingview.com/symbols/NASDAQ-PBM/). ## SEC filings and registration - **SEC name**: Psyence Biomedical Ltd. - **CIK**: 1985062 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PBM (Nasdaq), PBMWW (Nasdaq) - **State or country of incorporation**: A6 - **Fiscal year ends**: March 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: 121 RICHMOND STREET WEST PENTHOUSE, TORONTO - **Phone**: 27744604171 - **Shares outstanding**: 2,293,277 as of 2026-03-31 (20-F filed 2026-06-22) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1985062/000121390026111174/ea0309190-6k_psyence.htm) filed 2026-10-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1985062/000121390026106630/ea0307592-6k_psyence.htm) filed 2026-10-05 - [6-K](https://www.sec.gov/Archives/edgar/data/1985062/000121390026103733/ea0306807-6k_psyence.htm) filed 2026-09-28 - [6-K](https://www.sec.gov/Archives/edgar/data/1985062/000121390026102358/ea0306308-6k_psyence.htm) filed 2026-09-23 - [6-K](https://www.sec.gov/Archives/edgar/data/1985062/000121390026099451/ea0305327-6k_psyence.htm) filed 2026-09-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1985062/000121390026086123/ea0300579-6k_psyence.htm) filed 2026-08-06 - [20-F](https://www.sec.gov/Archives/edgar/data/1985062/000121390026070607/ea0294983-20f_psyence.htm) filed 2026-06-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1985062/000121390026065824/ea0293772-6k_psyence.htm) filed 2026-06-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001985062), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Psyence Biomedical Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PBM, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Psyence Biomedical Ltd. - **Ticker**: PBM - **Listing**: NASDAQ - **Country or territory**: Canada - **Business scope**: Pharmaceuticals: Major - **ISIN**: CA74449F4078 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PBM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/psyence-biomedical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Psyence Biomedical (PBM) news: offering", 2026-10-31, https://aibio.space/companies/psyence-biomedical/